Physician profile
Sameen Khalid
NPI 1265816052
$3,334.57
in general payments reported to CMS, 2019-2025
13 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2020: $20.15 · 2021: $716 · 2022: $246 · 2023: $398 · 2024: $158 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $998.79 | 2019 | |
| Abbvie INC. | $748.59 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $466.99 | 2021-2023 | Entyvio |
| Medtronic, INC. | $290.41 | 2021-2023 | Endoflip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.87 | 2021-2022 | |
| Exelixis INC. | $137.84 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $128.35 | 2024 | Iqirvo |
| Olympus America INC. | $94.82 | 2023 | Evis Exera III Video System Center |
| Pfizer INC. | $94.33 | 2019 | |
| Shire North American Group INC | $35.16 | 2019 | |
| Gilead Sciences, INC. | $32.56 | 2019 | |
| Boston Scientific Corporation | $31.88 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameen Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.